These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35230518)

  • 21. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
    Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
    Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
    Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT.
    O'Connor PJ; Pasik SD; van der Bom IM; Bishay V; Radaelli A; Kim E
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):295-301. PubMed ID: 31578635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis.
    Filippi L; Di Costanzo GG; D'Agostini A; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Nucl Med Commun; 2018 Sep; 39(9):845-852. PubMed ID: 29901488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
    Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
    Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
    Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.
    Iñarrairaegui M; Pardo F; Bilbao JI; Rotellar F; Benito A; D'Avola D; Herrero JI; Rodriguez M; Martí P; Zozaya G; Dominguez I; Quiroga J; Sangro B
    Eur J Surg Oncol; 2012 Jul; 38(7):594-601. PubMed ID: 22440743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area.
    Faron A; Sprinkart AM; Pieper CC; Kuetting DLR; Fimmers R; Block W; Meyer C; Thomas D; Attenberger U; Luetkens JA
    Eur J Radiol; 2020 Apr; 125():108889. PubMed ID: 32087468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
    Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
    J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MR Imaging Volumetric Response after Yttrium-90 Radioembolization for Colorectal Liver Metastases: Predictability at Baseline and Correlation with Survival.
    Lüdemann WM; Wieners G; Franz K; Hardt J; Pustelnik D; Böning G; Amthauer H; Gebauer B; Kahn J
    J Vasc Interv Radiol; 2023 Feb; 34(2):244-252.e1. PubMed ID: 36241152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
    Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
    Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
    Riaz A; Gates VL; Atassi B; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Baker T; Kulik L; Gupta R; Abecassis M; Benson AB; Omary R; Millender L; Kennedy A; Salem R
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):163-71. PubMed ID: 20421150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.